Borellini Flavia 4

What Happened
Flavia Borellini, a director of Revolution Medicines (RVMD), received equity awards on June 18, 2026: 1,191 restricted stock units (RSUs) and a derivative award covering 3,127 shares (total 4,318 shares). Both items were reported at $0.00 per share on the Form 4 (typical for grants/awards), so no purchase or sale proceeds were reported. This is a grant (compensation/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (appears filed one business day after the two-business-day deadline).
• Awards reported: 1,191 RSUs (footnote F1) and 3,127 derivative shares (award) reported at $0.00; total awarded = 4,318 shares.
• Vesting note (footnote F2): the derivative/option award vests in full on the earlier of the first anniversary of June 18, 2026 or immediately prior to the next Annual Meeting, subject to continued service.
• Shares beneficially owned after the transaction: not specified in the filing.
• Transaction code: “A” = Award/Grant.

Context

• These awards are routine director compensation and are not the same as an open-market purchase (which some investors view as a stronger bullish signal). The derivative portion is subject to vesting and has not been exercised or sold.
• Reporting at $0.00 indicates a grant; it does not imply market value or a cashless exercise. Do not infer trading intent from routine compensation grants.